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BACKGROUND: TACE/ADAM17 is a transmembranous protease that cleaves membrane-bound growth factors like EGFR ligands.
TACE-dependent proteolysis is regulated by its inhibitor, tissue inhibitor of metalloproteinases 3 (TIMP3). This study analyses the role
of TACE and TIMP3 mRNA expression in squamous cell carcinomas of the head and neck (HNSCCs).
METHODS: We analysed TACE and TIMP3 mRNA expression in HNSCCs from 106 patients by RNA in situ hybridisation.
RESULTS: TACE mRNA was upregulated in HNSCCs compared with dysplastic (Po0.05) and normal epithelia (Po0.001), with strong
hybridisation signals in 21.9% of invasive tumour tissues and 4.5% of dysplasia. Elevated mRNA levels were accompanied by increased
amounts of TACE protein in HNSCCs. TIMP3 mRNA expression in HNSCC-associated stroma was significantly higher than in the
stroma adjacent to dysplastic or normal epithelia. Expression of TACE mRNA in HNSCCs was associated with tumour stage
(P¼0.019) and regional lymph node metastasis (P¼0.009). Furthermore, levels of TACE mRNA in HNSCCs correlated with the
expression of TIMP3 mRNA in HNSCC-associated stroma. Concomitantly, patients expressing high levels of TACE and TIMP3
mRNA showed significantly reduced overall survival compared with those with low mRNA levels.
CONCLUSION: Our results indicate an important role of TACE and TIMP3 during development and progression of HNSCCs.
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Squamous cell carcinoma of the head and neck (HNSCC) is the
fifth most common cancer worldwide (Wong et al, 1996).
Treatment consists of surgery and/or radiotherapy and increas-
ingly chemoradiation, and is associated with reduced speech,
swallowing and quality of life. Unfortunately, the 5-year survival
rates have not significantly improved in the last two decades and
are still B50%. The poor prognosis, among others, reflects the
limited understanding of the (molecular) mechanisms of HNSCC
carcinogenesis itself as well as the lack of reliable HNSCC
biomarkers. In many affected patients, recurrences can be found
locally or regionally – associated with a high rate of mortality
(Woolgar, 2006). Lymph node metastasis strongly correlates with
tumour recurrence (Shah, 1990), and treatment failure is often
related to growth of disseminated tumour cells either locoregion-
ally causing locoregional recurrences or in lymph nodes outside
the original field of treatment (Pantel and Brakenhoff, 2004;
Woolgar, 2006).
Invasive growth of tumours is dependent on the degradation of
surrounding extracellular matrix (ECM), reflecting dysregulated
equilibrium between expression, activation, inhibition and recy-
cling of proteolytic enzymes. The ADAMs (A Disintegrin And
Metalloproteinase) are members of the metzincin (zinc-dependent
metalloproteases) superfamily (Kheradmand and Werb, 2002) and
are structurally highly related to matrix metalloproteinases
(MMPs). Currently, 430 ADAM proteins have been characterised,
exhibiting functions in fertilisation, neurogenesis and cancer. The
ADAMs are characterised by a typical multi-domain architecture
(reviewed in Primakoff and Myles, 2000), and some ADAMs
exhibit ‘sheddase’ activity; that is, membrane-tethered precursors
of cytokines, adhesion molecules and growth factors may be
proteolytically ‘shed’ into the extracellular environment. Although
an association of MMP expression with tumour cell invasion and
metastasis has been demonstrated for a number of malignancies
(reviewed in Egeblad and Werb, 2002), there is also increasing
evidence for a causal role of ADAM proteins in carcinogenesis and
tumour progression (Duffy et al, 2009).
The putative role of TACE (tumour necrosis factor (TNF)-a
converting enzyme), an enzymatically active member of the ADAM
sheddase family (ADAM17), during carcinogenesis has been
attributed to its ability to shed membrane-tethered molecules
crucial for tumour initiation and progression such as TNF-a
(Black et al, 1997), L-selectin (Peschon et al, 1998), ALCAM (Rosso
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set al, 2007) transforming growth factor (TGF)-a (Kenny and
Bissell, 2007) or type I TGF-b receptor (Liu et al, 2009). Clinically,
a potential role for TACE has been proposed for breast,
colon, prostate, hepatocellular and ovarian or endocrine cancers
(Borrell-Pages et al, 2003; Karan et al, 2003; Ding et al, 2004;
Blanchot-Jossic et al, 2005; Tanaka et al, 2005; Kirkegaard et al,
2008; McGowan et al, 2008). Intriguingly, TACE possesses a broad
substrate spectrum of growth factor and cytokine substrates,
whose cleavage leads to activation of the epidermal growth factor
receptor (EGFR) signalling cascade (e.g., TGF-a and amphiregulin)
(Yarden, 2001; Sunnarborg et al, 2002; Wang et al, 2009).
Furthermore, TACE activity also links extracellular G-protein-
coupled receptor (GPCR) activation to intracellular EGFR tyrosine
phosphorylation (Gschwind et al, 2003). Very recent results
indicate that TACE regulates EGFR expression through the
activation of Notch-1 in non-small cell lung cancer (Baumgart
et al, 2010). Collectively, an upregulation of TACE-mediated
sheddase activity would thus lead to elevated EGFR-derived
oncogenic drive in cancer cells, as it is widely accepted that
triggering the EGFR downstream cascade is crucial for carcinogen-
esis (Yarden, 2001; Ford and Grandis, 2003). This holds true
especially for HNSCCs (Ang et al, 2002). Physiologically, the
proteolytic activity of ADAM family members is mainly regulated
by its physiological inhibitor, the tissue inhibitor of metallopro-
teinases 3 (TIMP3) (Amour et al, 1998; Baker et al, 2002; Walker
and Rosenberg, 2009).
The aim of this study was to analyse the expression of TACE
mRNA in a series of 106 HNSCC specimens by RNA in situ
hybridisation. This is the first study relating TACE mRNA
expression in HNSCC to the amount of mRNA specific for TIMP3,
the primary inhibitor of TACE protease activity in vitro and
in vivo. Our results show that TACE mRNA is upregulated in the
majority of human HNSCCs in comparison with their parental
epithelia. Furthermore, high levels of TACE mRNA are associated
with an increased likelihood of metastasis into regional lymph
nodes, high tumour stage, strong stromal TIMP3 expression and
reduced overall survival of HNSCC patients.
MATERIALS AND METHODS
Patients
Paraffin-embedded HNSCCs from 106 consecutive patients
were selected following histological review from the files of
the Department of Oral Pathology, University Medical Center
Hamburg-Eppendorf, Germany. This study was approved by the
local ethics committee. All lesions collected between 1997 and 2004
were classified according to the most recent WHO criteria.
Tumours represent primary tumours and originated predomi-
nantly from the floor of mouth (30.2%), tongue (35.1%), buccal
mucosa (6.8%), upper or lower jaw (6.8%) or the palate (12.2%).
Remaining tumours were localised at maxillary or mandibular
gingivae, lips or in the oropharynx. The control group consisted of
10 tissue specimens from patients with non-neoplastic, inflamma-
tory disorders of the oral cavity. In addition, snap-frozen human
HNSCC samples and adjacent normal tissues were available
for immunoblot analysis. Follow-up data were available from
95 patients. The maximal duration of monitoring was 10 years.
Median observation time was 29 months. Out of 95 patients,
29 (30.5%) succumbed to the disease. The median survival time
of deceased patients was 11 months.
Cell lines and cell culture
The HNSCC cell line, JCRB 1027 SAT, was obtained from the Japan
Health Science Foundation, Health Science Research Resources
Bank. The other HNSCC cell lines were kindly provided
by Professor RH Brakenhoff (Department of Otolaryngology/
Head-Neck Surgery, VUMC Amsterdam, The Netherlands)
(Carey et al, 1990; Hermsen et al, 1996; de Nooij-van Dalen
et al, 2003; van Zeeburg et al, 2005). Cells were grown as
monolayers in DMEM medium (Invitrogen, Karlsruhe, Germany)
supplemented with 10% fetal calf serum (PAA Laboratories GmbH,
Pasching, Austria) and 2mML-glutamine (Invitrogen) at 371Ci na
humidified 10% CO2 atmosphere.
Antibodies
The goat polyclonal anti-human antibody sc-6416 (Santa Cruz
Biotechnology, Heidelberg, Germany) was raised against the
C-terminus of human TACE. The monoclonal mouse anti-human
EGFR antibody, clone E30, was raised against the purified,
denatured EGFR (Dako Cytomation, Glostrup, Denmark). Mouse
monoclonal antibody sc-7298 (Santa Cruz) was raised against the
C-terminus of human heat shock cognate protein 70 (HSC-70).
Horseradish-peroxidase (HRP) coupled goat-anti-mouse and
rabbit-anti-goat antibodies (Dako Cytomation) were used as
secondary antibodies.
Generation of digoxigenin-labelled cRNA probes
Total RNA was extracted from the human HNSCC cell lines
VUSCC-OE and UMSCC-14C using Trizol reagent (Invitrogen)
and transcribed into cDNA using oligo-dT-primed RT–PCR
(Invitrogen).
The following primers corresponding to nucleotides 2748–2772
and 3473-3494 of TACE mRNA (GenBank: NM_003183.4) were
used to amplify a 746-bp fragment: forward: 50-GGGAAGTGACTT
AGCAGATGCTGG-30, reverse: 50-TCCAAGTGCTGGGATTACAG
GC-30.
To amplify a 445-bp fragment, the following primers corre-
sponding to nucleotides 1448–1472 and 1870–1893 of human
TIMP3 mRNA (GenBank: NM_000362.4) were used: forward: 50-G
AGAGTCTCTGTGGCCTTAAGCTGG-30 reverse: 50-CTGGGAAGA
GTTAGTGTCCAAGGG-30.
PCR conditions were as follows: initial denaturation for 4min at
941C, followed by 34 cycles of 941C for 1min (denaturation), 641C
for 1min (annealing) and 721C for 1min (elongation). The
PCR product was analysed on a 1% agarose gel; desired bands
were excised and purified using the QIAquick Gel Extraction
Kit protocol (Qiagen, Hilden, Germany). The isolated DNA was
cloned into a pCRII-TOPO vector (Invitrogen) following the
vendor’s instructions and the correctness of the insert was
confirmed by sequencing. The vector was linearised using BamHI
or XhoI restriction digest to yield anti-sense or sense probes,
respectively.
To obtain cRNA probes from each strand of the cloned
sequence, T7 or SP6 polymerases were used. cRNA probes were
labelled with digoxigenin using a digoxigenin RNA labelling kit
(Roche, Mannheim, Germany) according to the manufacturer’s
information.
Probes were hydrolysed under alkaline conditions to facilitate
probe penetration into tissue. To determine the incubation time
necessary for cleavages resulting in a desired length of B200bp,
the following calculation was carried out: t¼(Li–Lf)/(k   Li  
Lf), with t¼time in min, Li¼initial length in Kb, Lf¼final length
of B200bp, and k¼constant 0.11cutsKb
–1min
–1. For hydrolysis,
the probe was suspended in 100mlo fd H 2O and 60ml of 0.2 M
Na2CO3 and 40ml of 0.2 M NaHCO3 were added before incubation
at 601C for the time span calculated. After stopping the reaction by
adding 10ml of 10% glacial acetic acid and 22mlo f3 M NaAc, pH
6.0, RNA was precipitated by adding 2ml of tRNA, 2.4mlo f1 M
MgCl2 and 600ml of ice-cold ethanol. Finally, labelled probes were
dissolved in 100ml Aqua bidest and the digoxigenin-labelling
efficiency was determined by dot blotting.
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Formalin-fixed paraffin-embedded tissue sections were deparaffi-
nised in p-xylene and subsequent washes in graded ethanol. All
solutions were prepared with diethylpyrocarbonate (DEPC)-
treated H2O to inactivate RNAse activity and prevent RNA
degradation. To facilitate accessibility of target mRNA, two initial
steps using 0.2N HCl for 20min and 0.3% Triton X-100 in PBS
for 15min were performed. Target mRNA-bound nucleoproteins
were removed by proteinase K incubation (5mgml
–1for 30min at
371C). Subsequently, the proteinase K activity was quenched
via treatment with 0.2% (w/v) glycine for 5min at 41C. Incubation
in 4% ice-cold paraformaldehyde (w/v in PBS) ensured proper
fixation of tissue onto slides. Acetylation (5mlml
–1 acetic
anhydride in 0.1 M triethanoleamine) reduced unspecific back-
ground signals. Before hybridisation, slides were dried at 501C for
1h. In an initial step (prehybridisation), the slides were immersed
in hybridisation buffer (50% deionised formamide; 1  Denhardt’s
solution; 100mgml
–1 Poly-A solution; 500mgml
–1 salmon sperm
DNA; 500mgml
–1 t-RNA) for 2.5h at 521C to block unspecific
binding. Hybridisation was performed for at least 6h at 521Ci n
hybridisation buffer containing 10% dextran sulphate with a
final amount of 50ng cRNA-DIG probe per slide. Washes with
increasing stringency were performed (2  SSC at RT for 15min;
1  in formamide solution (50% Tris-buffered formamide
containing 0.3 M NaCl, 1mM EDTA and 10mM DTT) at 601C for
10min; 2  SSC at RT for 3min; 0.1  SSC at 521C for 15min;
0.1  SSC at RT for 10min). To further remove unbound cRNA
probe, the tissue was subjected to RNAse A (0.5mlml
–1) digestion
for 30min. Specifically bound cRNA probe was detected using an
anti-DIG-antibody coupled to alkaline phosphatase with nitroblue
tetrazolium chloride/X-phosphate 5-bromo-4-chloro-3-indolyl-
phosphate (NBT/BCIP) (Roche Diagnostics, Mannheim, Germany)
as chromogenic substrate. After an appropriate incubation time
the reaction was stopped and sections were counterstained with
1% Nuclear Fast Red dye (Vector, Burlingame, CA, USA),
dehydrated using an ascending ethanol concentration chain and
p-xylene and finally mounted using Entellan mounting media
(Merck, Darmstadt, Germany).
Semiquantitative analysis of in situ hybridisation signals
In situ hybridisation signals were evaluated using a Zeiss Axioplan 2
light microscope (Go ¨ttingen, Germany). Slides were assessed by a
board-reviewed pathologist (LR) and two investigators (JWK and
SR) independently and blinded to the clinical details of the case.
Questionable results were evaluated again until consent was reached.
The intensity of TACE/TIMP3 in situ hybridisation scores in the
tumour was determined semiquantitatively according to the follow-
ing criteria: TACE/TIMP3
 ¼no signal, TACE/TIMP3
þ ¼weak,
TACE/TIMP3
þþ¼moderate and TACE/TIMP3
þþþ¼strong.
Furthermore, the frequency of positive cells was determined.
Histologically discriminable epithelia like normal epithelium (NE),
dysplastic epithelium (DE) and stromal areas (STR) adjacent to the
invasive tumour were similarly quantified. For subsequent survival
analysis and correlation with clinicopathological parameters, in situ
hybridisation scores in HNSCCs were grouped into only two
categories: TACE
lo,c o m p r i s i n gT A C E
  to TACE
þþmRNA signals;
and TACE
hi,o n l yT A C E
þþþsignals in at least 30% of tumour cells.
The intensity of TIMP3 mRNA in stromal tissues adjacent to the
tumour was also grouped into two categories: TIMP3
lo,n os i g n a l so r
signals of weak intensity in stromal cells; and TIMP
hi,m o d e r a t e
to strong TIMP3 hybridisation signals of stromal cells.
Immunohistochemistry
After deparaffinisation, tissue sections were pretreated with pro-
teinase K (DAKO) and subsequently endogenous peroxidase was
blocked in 0.03% hydrogen peroxide. Anti-EGFR antibody
was applied (1:100 dilution) overnight at 41C. Immunostaining
was developed using the peroxidase-labelled polymer and 3,30-
diaminobenzidine (DAB) substrate-chromogen solution. Nuclei
were counterstained with haemalaun.
Immunoblot analysis
The detailed methodology is described in Supplementary Materials
and Methods.
Statistical analysis
Statistical analysis was performed using SPSS for Windows,
Version 18.0 (SPSS Inc., Chicago, IL, USA). To test the significance
of differences among groups of clinicopathological parameters,
data were analysed using two-sided Fisher’s exact or w
2 test.
Upregulation of TACE or TIMP3 mRNA in situ hybridisation score
was shown using the two-sided sign test. The significance level was
defined as Po0.05. Kaplan–Meier survival analysis of uncensored
cases was performed using SPSS.
RESULTS
Expression of TACE mRNA
In a hypothesis-driven approach, we determined the expression
levels of TACE and TIMP3 mRNA by in situ hybridisation in a
training set comprising a series of commercially supplied
histopathologically defined HNSCC specimens (HNSCC tissue
micro array; US Biomax, Inc., Rockville, MD, USA). Interestingly,
the intensity of TACE or TIMP3 mRNA tended to be associated
with higher tumour stages (T-status) in this group of 57 evaluable
carcinomas (P¼0.067 or 0.09, respectively; Supplementary
Table S1). Prompted by this, we aimed to corroborate our findings
in a defined set of archived paraffin-embedded tissue from a
cohort of 106 HNSCC patients.
Hybridisation signals specific for TACE were found throughout
the oral mucosa with varying intensities between specimens
and tissues (Supplementary Table S2, Figure 1A and C). In situ
hybridisation with the control sense riboprobe yielded no signals
(Figure 1B and D). Signals also disappeared when samples
underwent an additional RNAse treatment (not shown). Hybridi-
sation signals specific for TACE were also found in non-epithelial
cells like vessel endothelial cells and lymphocytes (not shown).
Histologically NE adjacent to HNSCC was either negative for TACE
mRNA (71.9%, Figure 1E) or expressed it only weakly (25%) to
moderately (3.1%). Samples of patients suffering from non-
cancerous, inflammatory diseases of the oral cavity displayed
comparable levels of TACE mRNA in NE (not shown). In contrast,
only a few cases of DE adjacent to the tumours were negative for
TACE mRNA (27.3%); weak (31.8%) to intermediate (36.4%)
hybridisation signals were predominant (Figure 1A). Only a small
number of patients expressed high levels of TACE mRNA in DE
(4.5%). A comparable percentage of HNSCCs was negative
for TACE mRNA (19.0%), and similarly the majority of tumours
displayed weak (22.9%) to intermediate (36.2%) signals. A
considerable number of tumours, however, exhibited high
amounts of TACE mRNA (21.9%, Figure 1C), thus clearly differing
in signal intensity from dysplastic areas (Figure 1A). Stroma
associated with HNSCC was predominantly negative for TACE-
specific hybridisation signals (74%, Supplementary Table S2) and
showed, if any, weak (23%) or moderate (3%) amounts of TACE
mRNA. The upregulation of TACE mRNA in HNSCC compared
with NE (Po0.001, Figure 2A) and DE (Po0.05, Figure 2A) was
statistically significant. Finally, DE exhibited elevated levels of
TACE mRNA compared with NE (Po0.001, Figure 2B).
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in most HNSCC cases (data not shown in detail, representative
image in Figure 1L), a strong increase of EGFR protein expression
from NE to DE and carcinoma tissue was observed (Figure 1J–L).
Relationship between TACE mRNA expression and
clinicopathological parameters
To assess whether high levels of TACE mRNA correlate with
HNSCC progression, we defined TACE
lo and TACE
hi carcinomas
and juxtaposed levels of TACE mRNA with known clinicopatho-
logical parameters (Table 1). The nodal status was assessed in 91
patients, 30 of whom had lymph node metastases. We found no
statistical association of TACE mRNA levels with age or gender of
affected patients. Interestingly, 36.7% of lymph node-positive
(LN
þ) patients displayed high levels of TACE mRNA (TACE
hi).
In contrast, only 13.1% of lymph node-negative (LN
 ) patients
were scored as TACE
hi. The correlation between the amount of
TACE mRNA and the presence of metastases in regional lymph
nodes was statistically significant (P¼0.009). The positive
correlation of TACE mRNA levels with primary tumour stage
was also statistically significant (P¼0.019).
Expression of TACE protein
To elucidate whether TACE mRNA overexpression in human
HNSCC results in corresponding levels of translated TACE protein,
we conducted immunoblot analysis using an antibody specifically
recognising the carboxyterminal part of human TACE. To verify
antibody specificity, we analysed a panel of well-characterised
HNSCC cell lines for the expression of TACE protein. We found
two clearly discriminable bands migrating with an approximate
molecular mass of 110 and 90kD, respectively. The ratio between
cleaved and uncleaved TACE protein varied between different
HNSCC cell lines (Figure 3A). Based on the molecular mass,
these bands constitute the uncleaved precursor as well as the
enzymatically active mature TACE protein. The observed mole-
cular weight of TACE protein was in line with most other reports
utilising TACE-specific polyclonal antibodies (Blanchot-Jossic
et al, 2005; McGowan et al, 2007). To find out whether
TACE protein could also be detected in carcinoma tissue, we
analysed tissue lysates from four human HNSCC specimens.
Immunoblot showed heterogeneous TACE protein expression
exclusively in tumour but not in normal oral tissues (Figure 3B).
In HNSCC, the mature TACE isoform constituted the dominant
isoform.
Figure 1 TACE and TIMP3 mRNA expression were detected by RNA in situ hybridisation (A–I, hybridisation signals: blue). (A) Moderate TACE mRNA
expression in dysplastic epithelium and (C) strong TACE hybridisation signals in HNSCC. (E) No TACE mRNA expression in normal epithelium. Control
riboprobes in sense orientation against TACE ((B) control to (A), (D) control to (C), and TIMP3 (H)t o( G)) yielded no signals. Moderate to strong TIMP3
mRNA-specific signals are found in dysplastic epithelium (F), in HNSCC (G) and stromal areas adjacent to HNSCC (I). EGFR protein detected by
immunohistochemistry (J–L). EGFR protein is highly expressed in basal and parabasal cells of normal epithelium (J), dysplastic (K)a n dH N S C C( L) epithelia.
Slides were counterstained with nuclear fast red dye (in situ hybridisation, pink) and haematoxylin (immunohistochemistry, blue); original magnification:  200.
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Tissue inhibitor of metalloproteinases 3 mRNA was detected
throughout all oral tissues analysed (NE, DE and cancerous
lesions; Supplementary Table S3). Histologically NEs harboured
low levels or intermediate levels of TIMP3 mRNA; the same held
true for DEs (Figure 1F) and the majority of cancerous lesions
(Figure 1G, Supplementary Table S3). Yet, no statistically
significant upregulation of TIMP3 mRNA levels could be found
between these epithelial areas. One hallmark of TIMP3 biology is
the fact that this cell-secreted soluble molecule can be expressed
either by tumour cells at the invasion front or in the surrounding
stroma. Thus, TIMP3 mRNA levels were markedly increased in
stromal areas surrounding invasive HNSCC compared with DE
and NE (Figures 1I and 2C and Supplementary Table S3) and were
also elevated in the stroma adjacent to DE compared with NE
(Figure 2D and Supplementary Table S3).
Relationship between TIMP3 mRNA expression and
clinicopathological features
Expression levels of TIMP3 mRNA in the tumour tissues did not
correlate with clinicopathological parameters of the patients
analysed. However, considering tumour-associated stromal areas
separately resulted in a significant correlation of increased TIMP3
mRNA expression with a higher tumour stage (P¼0.031, Table 1).
Furthermore, a significant correlation between levels of TIMP3
mRNA in tumour-associated stromal cells and TACE mRNA in
tumour cells was detected (P¼0.022, Table 1).
Impact of TACE and TIMP3 mRNA overexpression on
overall survival of patients
Finally, we aimed to investigate a possible correlation between
TACE and TIMP3 mRNA expression levels and the overall survival
of patients. Of 95 affected patients with known follow-up data,
those individuals whose tumours showed TACE
hi mRNA expres-
sion levels exhibited reduced overall survival compared with those
with TACE
lo mRNA expression, as judged by Kaplan–Meier
analysis. This unfavourable prognosis proved to be statistically
significant (P¼0.026, log-rank test, Figure 4A). However, we could
not show that this influence on survival was independent of lymph
node metastasis (data not shown). There was also a correlation of
borderline significance between high TIMP3 mRNA levels in
tumour-associated stromal areas and a reduced overall survival
of HNSCC patients analysed (P¼0.058, Figure 4B). Combining the
results of TACE and TIMP3 mRNA detection, patients with both
high levels of TACE and TIMP3 mRNA had the worst clinical
outcome, followed by patients with either high levels of TACE or
TIMP3 mRNA levels. The most favourable overall survival was
observed in patients with low levels of TACE mRNA in tumour
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dysplastic epithelium
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n
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Figure 2 TACE in situ hybridisation signals in head and neck tissues and TIMP3 in situ hybridisation signals in stromal cells surrounding HNSCC, dysplastic
and normal epithelium. In situ hybridisation signals of paraffin sections were scored semiquantitatively. TACE mRNA expression levels were compared
between tumour and normal epithelium or tumour and dysplastic epithelium (A). Dysplastic areas were compared with normal epithelium (B). TIMP3
mRNA expression in stromal areas surrounding tumour epithelium were compared with normal or dysplastic epithelium (C). Stromal areas surrounding
dysplastic areas were compared with normal epithelium (D). Statistical significance was calculated using nonparametric sign test. The P-values of o0.05 were
defined as statistically significant (*Po0.05; **Po0.01; ***Po0.001).
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Figure 4C).
DISCUSSION
We determined the amount of TACE and TIMP3 mRNA in human
HNSCC using RNA in situ hybridisation as the method of choice,
as published reports and own studies quantifying TACE protein
levels using immunohistochemistry led to conflicting results,
probably because of poorly characterised antibodies (Merchant
et al, 2008).
The positive correlation between TACE transcript levels and
increasing malignancy of HNSCC argued for TACE mRNA
upregulation being an important early event in tumourigenesis
itself as well as in the transition from premalignant lesions to
HNSCC. Bioinformatic screens for differential TACE mRNA
expression using the Oncomine database (www.oncomine.org)
confirmed the highly significant (Po10
 6) increase in TACE
transcript levels in HNSCC specimens (Cromer et al, 2004).
Furthermore, in our study, TACE mRNA levels correlated with
nodal metastases and primary tumour size and concomitantly
corroborated a report describing the association between TACE
protein levels, nodal metastasis and local recurrences in a small
HNSCC cohort (Takamune et al, 2007). Recently, close correlations
between TACE sheddase activity and HNSCC tumour stage were
reported (Ge et al, 2009). Intriguingly, in our patient cohort,
elevated TACE mRNA levels in HNSCC correlated with reduced
patient survival. This may be related directly to the observation
that TACE mRNA levels parallel the degree of lymph node
metastasis, an independent prognostic marker for tumour
progression and patient survival.
We analysed the expression of TACE protein in human HNSCC
cell lines and HNSCC tumour samples and detected high levels of
both mature and immature TACE protein. In tumour tissue we
found a prevalence of the lower molecular weight, enzymatically
active TACE isoform. Further studies need to confirm the
correlation between TACE mRNA and enzymatically active TACE
protein levels. Conflicting migratory patterns of TACE proteins in
published immunoblot analyses (Takamune et al, 2007) might be
because of different antibodies used.
Thus, TACE represents one key regulator of EGFR ligand
availability (Sunnarborg et al, 2002) and bioactivity (Borrell-Pages
et al, 2003; Lemjabbar et al, 2003). Epidermal growth factor
receptor is widely accepted as a crucial signalling platform on
which growth factor signals converge, and the effect of its
overexpression in HNSCC tumours has been described extensively
(Ford and Grandis, 2003; Gschwind et al, 2003; Fischer et al, 2004;
Schafer et al, 2004). Interestingly, moderate and high levels of
EGFR protein were detected in the majority of HNSCCs analysed in
Table 1 Expression of TACE mRNA in HNSCC and TIMP3 mRNA in stromal tissues in relation to clinicopathological parameters
Clinicopathological feature
n TACE
lo TACE
hi P-value n TIMP3STR
lo TIMP3STR
hi P-value
Quantification ISH ISH
Age
p60 years 50 38 12 40.5 50 35 15 0.312
460 years 55 44 11 56 44 12
Sex
Male 69 53 16 40.5 71 51 20 0.364
Female 36 29 7 35 28 7
Nodal status
LN
  61 53 8 0.009 61 47 14 40.5
LN
+ 30 19 11 31 22 9
Tumour stage
T1 39 61 12 0.019 39 60 13 0.031
T2 34 34
T3 8 18 11 8 18 11
T4 21 21
Histological grading
G1 13 64 17 40.5 13 62 19 40.5
G2 68 68
G3 24 18 6 24 17 7
TIMP3 (ISH)
TIMP3STR
lo 77 64 13 0.022
TIMP3STR
hi 26 16 10
Abbreviations: HNSCC¼squamous cell carcinoma of the head and neck; TACE¼tumour necrosis factor (TNF)-a converting enzyme; LN¼lymph node; TIMP3¼tissue
inhibitor of metalloproteinases 3; ISH¼in situ hybridisation. Bold and italic entries indicate statistically significant values.
Anti-TACE
Anti-HSC70
VU120T
92-VU-059
JCRB:SAT
UMSCC22A
UMSCC14C
Pro-TACE (110 kDa)
Mature TACE (90 kDa)
T1
T2
T3
T4
Anti-TACE
Anti-HSC70
Pro-TACE (110 kDa)
MatureTACE (90 kDa)
N
Figure 3 Representative western blot showing TACE protein expres-
sion in (A) HNSCC cell lines and (B) human HNSCC (T1–4) and adjacent
normal tissue (N). Two distinct bands constitute unprocessed and cleaved
mature TACE protein. Blotting results obtained with an anti-HSC70
antibody were used as loading control.
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sthis study. Thus, elevated TACE levels might contribute to the
bioavailability of EGFR ligands in HNSCC, providing cancer cells
with high TACE expression levels with a selection advantage.
Kenny and Bissell (2007) showed that inhibition of TACE protease
activity blocked EGFR signalling, resulting in a reversion of the
malignant phenotype of T4-2 breast cancer cells. Inhibition of
TACE using selective inhibitors also decreased cell proliferation in
an in vitro model of colorectal cancer (Merchant et al, 2008).
Tissue inhibitor of metalloproteinase 3 exerts its anti-proteolytic
function either at the invasion front of an infiltrating HNSCC to
quench tumour-associated ECM degrading activity or in the
stroma itself, where soluble proteases liberate ECM-tethered
factors that assist the cancer cell in migration and invasion.
Proper balancing between proteolytic enzymes (e.g., MMPs) and
their cognate inhibitors (e.g., TIMPs) seems to be of importance
for cancer metastasis and invasion (Cruz-Munoz et al, 2006;
Wu et al, 2008). Our finding of TIMP3 upregulation in HNSCC
with increasing tumour stage is in contrast to a published report
that claimed a tumour-suppressor function for TIMP3, showing to
be frequently silenced by promoter hypermethylation during
HNSCC progression (Worsham et al, 2006). Comparing expression
levels of TIMP3 mRNA in TACE
lo and TACE
hi tumours,
we observed a positive correlation between levels of TIMP3 in
tumour-associated stromal tissues and TACE mRNA in HNSCC.
Furthermore, high expression of both tumour-associated TACE
and stromal TIMP3 mRNA led to worse clinical outcomes than
either factor independently. Hitherto, no reports linked TACE
activity to increased TIMP3 mRNA transcription, and thus this
effect probably constitutes a compensatory mechanism to counter-
balance the pathological increase in TACE sheddase activity. Yet,
it cannot be excluded that TIMP3 expression may also function to
promote tumour progression (Byrne et al, 1995).
Collectively, this study demonstrates the importance of TACE
and TIMP3 expression in HNSCC tumourigenesis and progression.
Further investigation is necessary to identify the key proteins
shedded by TACE that are pivotal for the development and
progression of these tumours.
ACKNOWLEDGEMENTS
We thank Malgorzata Stoupiec, Sonja Santjer and Oliver
Mauermann for excellent technical assistance and Dr Michael
Bubenheim (Institute for Medical Biometry and Epidemiology,
University Medical Center Hamburg-Eppendorf, Germany) for
supporting statistical analyses. Professor Dr RH Brakenhoff (VUMC
Amsterdam) is acknowledged for providing HNSCC cell lines
and critical reading of the manuscript. This work was supported
by the Deutsche Krebshilfe (70–2922 to REF, LR and KP).
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ,
Stephens PE, Shelley C, Hutton M, Knauper V, Docherty AJ, Murphy G
(1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3.
FEBS Lett 435: 39–44
Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK,
Milas L (2002) Impact of epidermal growth factor receptor expression on
survival and pattern of relapse in patients with advanced head and neck
carcinoma. Cancer Res 62: 7350–7356
Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors:
biological actions and therapeutic opportunities. J Cell Sci 115:
3719–3727
Baumgart A, Seidl S, Vlachou P, Michel L, Mitova N, Schatz N, Specht K,
Koch I, Schuster T, Grundler R, Kremer M, Fend F, Siveke JT, Peschel C,
Duyster J, Dechow T (2010) ADAM17 regulates epidermal growth factor
receptor expression through the activation of Notch1 in non-small cell
lung cancer. Cancer Res 70: 5368–5378
Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF,
Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N,
Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ,
March CJ, Cerretti DP (1997) A metalloproteinase disintegrin that
releases tumour-necrosis factor-alpha from cells. Nature 385: 729–733
Blanchot-Jossic F, Jarry A, Masson D, Bach-Ngohou K, Paineau J, Denis
MG, Laboisse CL, Mosnier JF (2005) Up-regulated expression of
ADAM17 in human colon carcinoma: co-expression with EGFR in
neoplastic and endothelial cells. J Pathol 207: 156–163
Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J (2003) TACE is
required for the activation of the EGFR by TGF-alpha in tumors. EMBO J
22: 1114–1124
TACElo/TIMP3lo
P=0.011
TACElo/TIMP3hi
TACEhi/TIMP3hi
TACEhi/TIMP3lo
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
 
(
%
) 80
100
60
40
20
0
0 1 02 03 04 05 06 0
Survival (months)
TIMP3lo
TIMP3hi
P=0.058
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
 
(
%
)
80
100
60
40
20
0
0 1 02 03 04 05 06 0
Survival (months)
TACElo
TACEhi
P=0.026
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
 
(
%
)
80
100
60
40
20
0
0 1 02 03 04 05 06 0
Survival (months)
Figure 4 Kaplan–Meier survival curve demonstrating percentage of
overall survival in patients whose tumours harboured high vs low levels
of TACE mRNA in tumour cells (A) and TIMP3 mRNA in stromal cells (B).
Overall survival of patients with high TACE and TIMP3 mRNA levels, high
TACE or high TIMP3 mRNA levels or low TACE and low TIMP3 mRNA
levels in tumour and stromal cells, respectively (C).
TACE and TIMP3 mRNA in HNSCC
J-W Kornfeld et al
144
British Journal of Cancer (2011) 104(1), 138–145 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sByrne JA, Tomasetto C, Rouyer N, Bellocq JP, Rio MC, Basset P (1995) The
tissue inhibitor of metalloproteinases-3 gene in breast carcinoma:
identification of multiple polyadenylation sites and a stromal pattern
of expression. Mol Med 1: 418–427
Carey TE, Wolf GT, Baker SR, Krause CJ (1990) Cell surface antigen
expression and prognosis. In Head Neck Cancer 2, Fee WE, Goepfert H,
Johns ME, Ward PH (eds), pp77–82. BC Deckes: Toronto
Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, Lemaire F, Young J,
Dembele D, Thibault C, Muller D, Poch O, Abecassis J, Wasylyk B (2004)
Identification of genes associated with tumorigenesis and metastatic
potential of hypopharyngeal cancer by microarray analysis. Oncogene 23:
2484–2498
Cruz-Munoz W, Sanchez OH, Di Grappa M, English JL, Hill RP, Khokha R
(2006) Enhanced metastatic dissemination to multiple organs by
melanoma and lymphoma cells in timp-3 /  mice. Oncogene 25:
6489–6496
de Nooij-van Dalen AG, van Dongen GA, Smeets SJ, Nieuwenhuis EJ,
Stigter-van Walsum M, Snow GB, Brakenhoff RH (2003) Characterization
of the human Ly-6 antigens, the newly annotated member Ly-6K
included, as molecular markers for head-and-neck squamous cell
carcinoma. Int J Cancer 103: 768–774
Ding X, Yang LY, Huang GW, Wang W, Lu WQ (2004) ADAM17 mRNA
expression and pathological features of hepatocellular carcinoma. World
J Gastroenterol 10: 2735–2739
Duffy MJ, McKiernan E, O0Donovan N, McGowan PM (2009) Role
of ADAMs in cancer formation and progression. Clin Cancer Res 15:
1140–1144
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases
in cancer progression. Nat Rev Cancer 2: 161–174
Fischer OM, Hart S, Gschwind A, Prenzel N, Ullrich A (2004) Oxidative
and osmotic stress signaling in tumor cells is mediated by ADAM
proteases and heparin-binding epidermal growth factor. Mol Cell Biol 24:
5172–5183
Ford AC, Grandis JR (2003) Targeting epidermal growth factor receptor in
head and neck cancer. Head Neck 25: 67–73
Ge L, Baskic D, Basse P, Vujanovic L, Unlu S, Yoneyama T, Vujanovic A,
Han J, Bancovic D, Szczepanski MJ, Hunt JL, Herbermann RB, Gollin SM,
Ferris RL, Whiteside TL, Myers EN, Vujanovic NL (2009) Sheddase
activity of tumor necrosis factor-alpha converting enzyme is increased
and prognostically valuable in head and neck cancer. Cancer Epidemiol
Biomarkers Prev 18: 2913–2922
Gschwind A, Hart S, Fischer OM, Ullrich A (2003) TACE cleavage of
proamphiregulin regulates GPCR-induced proliferation and motility
of cancer cells. EMBO J 22: 2411–2421
Hermsen MA, Joenje H, Arwert F, Welters MJ, Braakhuis BJ, Bagnay M,
Westerveld A, Slater R (1996) Centromeric breakage as a major cause of
cytogenetic abnormalities in oral squamous cell carcinoma. Genes
Chromosomes Cancer 15: 1–9
Karan D, Lin FC, Bryan M, Ringel J, Moniaux N, Lin MF, Batra SK (2003)
Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3
(tissue inhibitor of metalloproteinase-3) in human prostatic adenocarci-
nomas. Int J Oncol 23: 1365–1371
Kenny PA, Bissell MJ (2007) Targeting TACE-dependent EGFR ligand
shedding in breast cancer. J Clin Invest 117: 337–345
Kheradmand F, Werb Z (2002) Shedding light on sheddases: role in growth
and development. Bioessays 24: 8–12
Kirkegaard T, Naresh A, Sabine VS, Tovey SM, Edwards J, Dunne B,
Cooke TG, Jones FE, Bartlett JM (2008) Expression of tumor necrosis
factor alpha converting enzyme in endocrine cancers. Am J Clin Pathol
129: 735–743
Lemjabbar H, Li D, Gallup M, Sidhu S, Drori E, Basbaum C (2003) Tobacco
smoke-induced lung cell proliferation mediated by tumor necrosis
factor alpha-converting enzyme and amphiregulin. J Biol Chem 278:
26202–26207
Liu C, Xu P, Lamouille S, Xu J, Derynck R (2009) TACE-mediated
ectodomain shedding of the type I TGF-beta receptor downregulates
TGF-beta signaling. Mol Cell 35: 26–36
McGowan PM, McKiernan E, Bolster F, Ryan BM, Hill AD, McDermott EW,
Evoy D, O0Higgins N, Crown J, Duffy MJ (2008) ADAM-17 predicts
adverse outcome in patients with breast cancer. Ann Oncol 19:
1075–1081
McGowan PM, Ryan BM, Hill AD, McDermott E, O0Higgins N, Duffy MJ
(2007) ADAM-17 expression in breast cancer correlates with variables of
tumor progression. Clin Cancer Res 13: 2335–2343
Merchant NB, Voskresensky I, Rogers CM, Lafleur B, Dempsey PJ,
Graves-Deal R, Revetta F, Foutch AC, Rothenberg ML, Washington
MK, Coffey RJ (2008) TACE/ADAM-17: a component of the epidermal
growth factor receptor axis and a promising therapeutic target in
colorectal cancer. Clin Cancer Res 14: 1182–1191
Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev
Cancer 4: 448–456
Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC,
Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N,
Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ,
Black RA (1998) An essential role for ectodomain shedding in
mammalian development. Science 282: 1281–1284
Primakoff P, Myles DG (2000) The ADAM gene family: surface proteins
with adhesion and protease activity. Trends Genet 16: 83–87
Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S,
Orengo AM, Puppo A, Ferrini S, Fabbi M (2007) The ALCAM shedding
by the metalloprotease ADAM17/TACE is involved in motility of ovarian
carcinoma cells. Mol Cancer Res 5: 1246–1253
Schafer B, Gschwind A, Ullrich A (2004) Multiple G-protein-coupled
receptor signals converge on the epidermal growth factor receptor to
promote migration and invasion. Oncogene 23: 991–999
Shah JP (1990) Patterns of cervical lymph node metastasis from
squamous carcinomas of the upper aerodigestive tract. Am J Surg 160:
405–409
Sunnarborg SW, Hinkle CL, Stevenson M, Russell WE, Raska CS,
Peschon JJ, Castner BJ, Gerhart MJ, Paxton RJ, Black RA, Lee DC
(2002) Tumor necrosis factor-alpha converting enzyme (TACE) regulates
epidermal growth factor receptor ligand availability. J Biol Chem 277:
12838–12845
Takamune Y, Ikebe T, Nagano O, Nakayama H, Ota K, Obayashi T, Saya H,
Shinohara M (2007) ADAM-17 associated with CD44 cleavage
and metastasis in oral squamous cell carcinoma. Virchows Arch 450:
169–177
Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A,
Mizushima H, Maehara Y, Mekada E, Nakano H (2005) Clinical
significance of heparin-binding epidermal growth factor-like growth
factor and a disintegrin and metalloprotease 17 expression in human
ovarian cancer. Clin Cancer Res 11: 4783–4792
van Zeeburg HJ, Snijders PJ, Pals G, Hermsen MA, Rooimans MA, Bagby G,
Soulier J, Gluckman E, Wennerberg J, Leemans CR, Joenje H,
Brakenhoff RH (2005) Generation and molecular characterization of
head and neck squamous cell lines of fanconi anemia patients. Cancer
Res 65: 1271–1276
Walker EJ, Rosenberg GA (2009) TIMP-3 and MMP-3 contribute to delayed
inflammation and hippocampal neuronal death following global
ischemia. Exp Neurol 216: 122–131
Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL (2009)
Transforming growth factor beta induces clustering of HER2 and
integrins by activating Src-focal adhesion kinase and receptor associa-
tion to the cytoskeleton. Cancer Res 69: 475–482
Wong DT, Todd R, Tsuji T, Donoff RB (1996) Molecular biology of human
oral cancer. Crit Rev Oral Biol Med 7: 319–328
Woolgar JA (2006) Histopathological prognosticators in oral and
oropharyngeal squamous cell carcinoma. Oral Oncol 42: 229–239
Worsham MJ, Chen KM, Meduri V, Nygren AO, Errami A, Schouten JP,
Benninger MS (2006) Epigenetic events of disease progression in head
and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg
132: 668–677
Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC (2008)
Prognostic significance of MMP-9 and TIMP-1 serum and tissue
expression in breast cancer. Int J Cancer 122: 2050–2056
Yarden Y (2001) The EGFR family and its ligands in human cancer:
signalling mechanisms and therapeutic opportunities. Eur J Cancer
37(Suppl 4): S3–S8
TACE and TIMP3 mRNA in HNSCC
J-W Kornfeld et al
145
British Journal of Cancer (2011) 104(1), 138–145 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s